Skip to the reference

Reference desk / Entry

Tesamorelin

Also listed as: Egrifta WR

Read the scope first. Then use the note and questions to examine what the evidence can answer.

Scoped product status
Approved product
Evidence label
Randomized evidence
Status as of

Reference fields

References for these fields are listed together in Sources.

Product and use scope
Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Route context
Specified subcutaneous formulation.
Mechanism
Stimulates growth-hormone release.
Evidence
A randomized trial measured visceral fat.
Limitations
Not for weight management.
Safety
Active malignancy is a contraindication.

A question worth making clear

Treat an outcome measure as a deliberate description with boundaries. Find the rule used to turn an experience or observation into a value, and ask which distinctions that rule preserves. If several different experiences could receive the same value, identify what additional description would separate them. This does not require dismissing the measure. It requires being clear about the question it was built to answer. In a shared discussion, describe both what the value captures and what it leaves unspecified before deciding whether it speaks to the concern being raised.

  1. What features of an experience does this measurement preserve in its final value?
  2. Could different experiences receive the same value under the measurement rule?
  3. Which additional description would address the part of our question left unspecified?

Sources

Each date below belongs to the supplied source record. The references support the entry as a group.